kentucky glp-1 intestinal paralysis lawsuit Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs Lawsuit for Diabetes Medicine

For clinicians and patients, this is a moment of transition

What concerns me most is the amount of misinformation being spread by individuals who have never prescribed these medications, never followed patients longitudinally, and often rely on fear rather than evidence

Lilly plans regulatory submissions in 2025 for obesity and in 2026 for type 2 diabetes

Explore the emerging evidence, safety considerations, and how these medications compare to FDA-approved BED treatments

Package Highlights: 30-day supply (30 servings)

June 6, 2025 A large retrospective review of more than 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events and inpatient admissions